Alnylam Pharmaceuticals Receivables

Alnylam Pharmaceuticals (ALNY) currently reports a receivables of $880M as of March 2026. That compares with $420M in the prior-year period — up 111.5% year over year. Use the charts on this page to explore Alnylam Pharmaceuticals's receivables history and peer comparisons.

Alnylam Pharmaceuticals's receivables increased from $420M to $880M — a 111.5% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Alnylam Pharmaceuticals reported $880M in receivables as of March 2026. That compares with $420M in the prior-year period — up 111.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $880M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Alnylam Pharmaceuticals, and consider following ALNY for alerts when major investors trade the stock.

Alnylam Pharmaceuticals is classified in the Healthcare sector. On receivables, it currently shows $880M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ALNY with unrelated industries.